Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First survival data from Phase I Dose Expansion in tough-to-treat elderly
Trial is designed to advance pelareorep's clinical development in China, the world's second-largest pharmaceutical market SAN DIEGO and CALGARY, AB, Oct. 14, 2021 /PRNewswire/ -- Oncolytics
THR-687 is a potent pan-RGD integrin antagonist holding potential as a next generation first line therapy for DME, currently a $4.5 billion market opportunity THR-687 also holds promise for treatment
DJ Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting Arix Bioscience
The European Union's drug regulator said it was evaluating a marketing authorisation for an antibody cocktail developed by Roche and Regeneron for treatment and prevention of COVID-19 in people above... | October 11, 2021